减肥药物利莫那班的疗效与安全性。 - Suppr

Suppr

超能文献

Efficacy and safety of the weight-loss drug rimonabant.

作者信息

Després Jean-Pierre, Van Gaal Luc, Pi-Sunyer Xavier, Scheen André

出版信息

Lancet. 2008 Feb 16;371(9612):555; author reply 556-7. doi: 10.1016/S0140-6736(08)60261-5.

DOI:10.1016/S0140-6736(08)60261-5

PMID:18280320

Abstract

摘要

相似文献

Efficacy and safety of the weight-loss drug rimonabant.减肥药物利莫那班的疗效与安全性。

Lancet. 2008 Feb 16;371(9612):555; author reply 556-7. doi: 10.1016/S0140-6736(08)60261-5.

Efficacy and safety of the weight-loss drug rimonabant.

Lancet. 2008 Feb 16;371(9612):555-6; author reply 556-7. doi: 10.1016/S0140-6736(08)60262-7.

Depression and weight loss: opposite outcome for surgery and rimonabant?

Obes Rev. 2008 Sep;9(5):504-7. doi: 10.1111/j.1467-789X.2008.00512.x. Epub 2008 Jul 11.

Effect of rimonabant on weight and cardiometabolic risk factors.利莫那班对体重及心血管代谢危险因素的影响。

JAMA. 2006 Aug 9;296(6):649-50; author reply 650-1. doi: 10.1001/jama.296.6.649.

Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials.减肥药物利莫那班的疗效与安全性：随机试验的荟萃分析

Lancet. 2007 Nov 17;370(9600):1706-13. doi: 10.1016/S0140-6736(07)61721-8.

Depression and anxiety with rimonabant.

Lancet. 2007 Nov 17;370(9600):1671-2. doi: 10.1016/S0140-6736(07)61705-X.

Rimonabant: suicide and depression. Depression and suicidal tendencies are about twice as frequent with rimonabant as with placebo.利莫那班：自杀与抑郁。服用利莫那班出现抑郁和自杀倾向的频率约为服用安慰剂的两倍。

Prescrire Int. 2007 Dec;16(92):250.

[Still questions around the slimming agent rimobant. Not approved in USA because of the risk of mental adverse effects].[关于减肥药物利莫那班仍存在疑问。因其存在精神方面不良反应的风险，在美国未获批准]

Lakartidningen. 2007 Dec 19;104(51-52):3879-81.

[Antiobesity drugs--new limitations].[抗肥胖药物——新的局限性]

Rev Med Suisse. 2007 Nov 28;3(135):2753.

Rimonabant, obesity and diabetes.利莫那班、肥胖与糖尿病。

Prescrire Int. 2007 Jun;16(89):122.

引用本文的文献

Neutral CB1 Receptor Antagonists as Pharmacotherapies for Substance Use Disorders: Rationale, Evidence, and Challenge.中性 CB1 受体拮抗剂作为物质使用障碍的药物治疗：原理、证据和挑战。

Cells. 2022 Oct 17;11(20):3262. doi: 10.3390/cells11203262.

Molecular Alterations of the Endocannabinoid System in Psychiatric Disorders.精神疾病中环核苷酸系统的分子改变。

Int J Mol Sci. 2022 Apr 26;23(9):4764. doi: 10.3390/ijms23094764.

Multi-Target Approaches in Metabolic Syndrome.代谢综合征的多靶点治疗方法

Front Pharmacol. 2021 Mar 12;11:554961. doi: 10.3389/fphar.2020.554961. eCollection 2020.

Behavioral effects of the cannabinoid CB1 receptor allosteric modulator ORG27569 in rats.大麻素 CB1 受体别构调节剂 ORG27569 对大鼠行为的影响。

Pharmacol Res Perspect. 2014 Dec;2(6):e00069. doi: 10.1002/prp2.69. Epub 2014 Aug 24.

Use of CHAID decision trees to formulate pathways for the early detection of metabolic syndrome in young adults.使用 CHAID 决策树制定年轻人代谢综合征早期检测的途径。

Comput Math Methods Med. 2014;2014:242717. doi: 10.1155/2014/242717. Epub 2014 Apr 10.

Neurogenetics and Nutrigenomics of Neuro-Nutrient Therapy for Reward Deficiency Syndrome (RDS): Clinical Ramifications as a Function of Molecular Neurobiological Mechanisms.奖赏缺乏综合征（RDS）神经营养疗法的神经遗传学与营养基因组学：作为分子神经生物学机制函数的临床影响

J Addict Res Ther. 2012 Nov 27;3(5):139. doi: 10.4172/2155-6105.1000139.

Cannabinoid receptor 1 (CB1) antagonism enhances glucose utilisation and activates brown adipose tissue in diet-induced obese mice.大麻素受体 1（CB1）拮抗剂增强肥胖小鼠的葡萄糖利用并激活棕色脂肪组织。

Diabetologia. 2011 Dec;54(12):3121-31. doi: 10.1007/s00125-011-2302-6. Epub 2011 Oct 11.

Neuropsychiatric adverse effects of centrally acting antiobesity drugs.中枢作用减肥药的神经精神不良反应。

CNS Neurosci Ther. 2011 Oct;17(5):490-505. doi: 10.1111/j.1755-5949.2010.00172.x. Epub 2010 Jul 7.

Drugs associated with more suicidal ideations are also associated with more suicide attempts.与更多自杀意念相关的药物也与更多自杀企图相关。

PLoS One. 2009 Oct 2;4(10):e7312. doi: 10.1371/journal.pone.0007312.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验